Semaglutide (administered by DV3396 pen)

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

Healthy Volunteers Diabetes Mellitus, Type 2Healthy Volunteers ObesityHealthy Volunteers OverweightObesityOverweight

Phase 1

A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

TerminatedNCT04012255

Novo Nordisk A/SObesity, Overweight

Start: 2019-07-15End: 2019-10-22Updated: 2019-10-23

Phase 2

A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

CompletedNCT04007107

Novo Nordisk A/SHealthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Obesity, Healthy Volunteers Overweight

Start: 2019-06-27End: 2019-09-04Updated: 2020-08-04

A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

CompletedNCT04143945

Novo Nordisk A/SHealthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Obesity, Healthy Volunteers Overweight

Start: 2019-10-28End: 2020-01-04Updated: 2021-01-20